Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Retained Earnings: 2020-2024

Historic Retained Earnings for Apellis Pharmaceuticals (APLS) over the last 5 years, with Dec 2024 value amounting to -$3.0 billion.

  • Apellis Pharmaceuticals' Retained Earnings changed negligibly% to -$3.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.0 billion, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of -$3.0 billion for FY2024, which is 6.97% down from last year.
  • Apellis Pharmaceuticals' Retained Earnings amounted to -$3.0 billion in FY2024, which was down 6.97% from -$2.8 billion recorded in FY2023.
  • Apellis Pharmaceuticals' Retained Earnings' 5-year high stood at -$926.3 million during FY2020, with a 5-year trough of -$3.0 billion in FY2024.
  • For the 3-year period, Apellis Pharmaceuticals' Retained Earnings averaged around -$2.7 billion, with its median value being -$2.8 billion (2023).
  • Data for Apellis Pharmaceuticals' Retained Earnings shows a maximum YoY plummeted of 78.84% (in 2021) over the last 5 years.
  • Apellis Pharmaceuticals' Retained Earnings (Yearly) stood at -$926.3 million in 2020, then slumped by 78.84% to -$1.7 billion in 2021, then tumbled by 39.37% to -$2.3 billion in 2022, then dropped by 22.90% to -$2.8 billion in 2023, then decreased by 6.97% to -$3.0 billion in 2024.